MiniMed Group (MMED) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
21 Aug, 2026Executive summary
Annual meeting scheduled for October 9, 2026, to be held virtually for shareholder participation.
Shareholders are encouraged to review proxy materials and vote by October 8, 2026, 11:59 PM ET.
Voting matters and shareholder proposals
Election of four directors: David J. Endicott, D. Keith Grossman, Kevin E. Lofton, and Timothy A. Wicks, all recommended for approval.
Ratification of PricewaterhouseCoopers LLP as independent auditor for fiscal year ending April 30, 2027.
Advisory vote to approve named executive officer compensation (say-on-pay), recommended for approval.
Advisory vote on frequency of say-on-pay votes, with a recommendation for annual (1 year) votes.
Provision for other business to be addressed as may properly come before the meeting.
Board of directors and corporate governance
Board recommends all director nominees for election at the annual meeting.
Latest events from MiniMed Group
- Revenue up 16.6% to $843M, with strong pump and CGM growth and improved profitability.MMED
Q2 2026 - New product launches and upcoming innovations drive growth and market expansion, especially for Type 2.MMED
Wells Fargo 21st Annual Healthcare Conference - Strong growth, innovation, and clinical outcomes drive robust financials and global expansion.MMED
Investor presentation - Q1 FY27 delivered 16% organic revenue growth and raised full-year guidance to 10.5%.MMED
Q1 2027 - Proxy covers director elections, auditor ratification, and executive pay post-separation.MMED
Proxy filing - AID market growth accelerates with new launches, integrated tech, and global execution focus.MMED
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Innovation and global scale fuel strong growth, margin expansion, and clinical leadership.MMED
Investor presentation - Record $3B+ revenue, strong international growth, and FY27 guidance for 10% organic growth.MMED
Q4 2026 - Q3 sales up 15% YoY, but net loss widened due to restructuring and a $157M royalty charge.MMED
Q3 2026